AMRI announces CFO transition
Michael M. Nolan, senior vice president and chief financial officer, will be departing Albany Molecular Research (AMRI), a global contract research and manufacturing organization. Nolan will remain with AMRI through February 2015 to support an orderly transition. Felicia Ladin will join the company in the same role, effective Feb. 4, 2015.
Ladin brings more than 20 years of finance, accounting and tax management experience to AMRI. A CPA by training, Ladin has spent the majority of her career in the pharmaceutical industry, most recently as senior vice president, CFO, Global Specialty Medicines at Teva Pharmaceuticals.